YAP101 / YAP Therapeutics - LARVOL DELTA

Gene Therapy Targeting the Hippo Pathway for In Vivo Cardiac Regeneration in Ischemic Heart Failure (ASGCT 2025) - "By coordinating in vivo cardiomyocyte cell division, vascular recruitment, and fibrosis reduction, YAP101 activates cardiac regeneration, leading to improved cardiac function and offering a potential breakthrough treatment for ischemic heart failure. Disease Focus of Abstract:Cardiovascular/Heart Disease"

Gene therapy • Preclinical • Cardiovascular • Congestive Heart Failure • Fibrosis • Gene Therapies • Heart Failure • Immunology • Myocardial Infarction

SALVADOR-HF: Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: YAP Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure